ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
0
views
0
references
Top references
cited by
1
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,152
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
FDA approves lorlatinib for metastatic ALK-positive NSCLC
Author(s):
Publication date:
2023
Read this article at
ScienceOpen
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Karger: Oncology
Data availability:
ScienceOpen disciplines:
Oncology & Radiotherapy
Comments
Comment on this article
Sign in to comment
Similar content
2,152
Abstract CT044: efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations
Authors:
A.T. Shaw
,
J-F Martini
,
B Besse
Esophageal Stricture Caused by ALK-Positive NSCLC Esophageal Metastasis Resolved After a Few Days of Lorlatinib Therapy Without Stent Placement
Authors:
Vito Longo
,
Annamaria Catino
,
Michele Montrone
…
LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): results of the phase III crown study
Authors:
B Solomon
,
T.M. Bauer
,
F de Marinis
…
See all similar
Cited by
1
Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase‑positive non‑small cell lung cancer: A case report
Authors:
Huan Wang
,
Zhenyan Wu
,
Guangqing Shi
…
See all cited by